Log in with your email address username.

×

Important notice

doctorportal Learning is on the move as we will be launching a new website very shortly. If you would like to sign up to dp Learning now to register for CPD learning or to use our CPD tracker, please email support@doctorportal.com.au so we can assist you. If you are already signed up to doctorportal Learning, your login will work in the new site so you can continue to enrol for learning, complete an online module, or access your CPD tracker report.

To access and/or sign up for other resources such as Jobs Board, Bookshop or InSight+, please go to www.mja.com.au, or click the relevant menu item and you will be redirected.

All other doctorportal services, such as Find A Doctor, are no longer available.

[Comment] Optimal duration of trastuzumab for early HER2-positive breast cancer

Four pivotal randomised trials1–3 have shown that the addition of trastuzumab, a monoclonal antibody targeting the HER2 receptor, to adjuvant chemotherapy results in significant improvements in disease-free survival and overall survival for patients with early stage HER2-positive breast cancer. The HERA trial1,4 differed from the North American NSABP B-31 and NCCTG 9831 trials3 because it mandated completion of all adjuvant chemotherapy before administration of trastuzumab, and randomly assigned patients to none, or 1 or 2 years of trastuzumab.

email